老板办公室乳摸GIF动态图,色婷婷亚洲一区二区三区,国产全是老熟女太爽了,欧美极度残忍变态另类电影
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2015.02.17
關(guān)于2015年度日常關(guān)聯(lián)交易預(yù)計(jì)的公告
2015.01.28
關(guān)于子公司醫(yī)療器械產(chǎn)品完成歐盟注冊(cè)的公告
2015.01.15
關(guān)于子公司醫(yī)療器械產(chǎn)品完成歐盟注冊(cè)的公告
2014.12.12
關(guān)于公司使用自有資金購(gòu)買低風(fēng)險(xiǎn)理財(cái)產(chǎn)品的進(jìn)展公告
2014.12.03
關(guān)于公司使用自有資金對(duì)TPG BIOTECHNOLOGY PARTNERS IV, L.P.進(jìn)行投資的進(jìn)展公告
2014.12.03
關(guān)于公司使用自有資金購(gòu)買低風(fēng)險(xiǎn)理財(cái)產(chǎn)品的進(jìn)展公告
2014.11.26
關(guān)于全資子公司使用自有資金對(duì)CANTEX進(jìn)行投資的進(jìn)展公告
2014.11.21
關(guān)于全資子公司使用自有資金對(duì)CANTEX進(jìn)行投資的公告
2014.11.21
第三屆董事會(huì)第六次會(huì)議決議公告
2014.11.20
2014年第四次臨時(shí)股東大會(huì)決議公告
第一頁(yè)
上一頁(yè)
106
107
108
109
110
下一頁(yè)
最后一頁(yè)
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright ? 2024 Hepalink Group. All Rights Reserved.
